| Mohammed Mogri, MD | |
|
3600 Gaston Avenue, Suite 960, Dallas, TX 75246 | |
| (214) 820-8030 | |
| (214) 818-9678 |
| Full Name | Mohammed Mogri |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 20 Years |
| Location | 3600 Gaston Avenue, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568607109 | NPI | - | NPPES |
| 102719890 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD445022 (Pennsylvania) | Secondary |
| 207R00000X | Internal Medicine | R0455 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor University Medical Center | Dallas, TX | Hospital |
| Baylor Scott & White Heart & Vascular Hospital - Dallas | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthtexas Provider Network | 1355254210 | 1810 |
News Archive
Researchers at the University of Toronto examined fungi in the mucus of patients with cystic fibrosis and discovered how one particularly cunning fungal species has evolved to defend itself against neighbouring bacteria.
A researcher from the University of Houston has created a form of recombinant insulin that could potentially address some of the biggest concerns about the lifesaving drug, including its price.
Researchers at the University of Cincinnati have received a $3.2 million grant from the National Institute of Neurological Diseases to study the use of neuroimaging to pinpoint the risk factors of stroke recurrence.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 5 days ago
| Entity Name | Healthtexas Provider Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760488936 PECOS PAC ID: 1355254210 Enrollment ID: O20040727001187 |
News Archive
Researchers at the University of Toronto examined fungi in the mucus of patients with cystic fibrosis and discovered how one particularly cunning fungal species has evolved to defend itself against neighbouring bacteria.
A researcher from the University of Houston has created a form of recombinant insulin that could potentially address some of the biggest concerns about the lifesaving drug, including its price.
Researchers at the University of Cincinnati have received a $3.2 million grant from the National Institute of Neurological Diseases to study the use of neuroimaging to pinpoint the risk factors of stroke recurrence.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mohammed Mogri, MD 3600 Gaston Avenue, Suite 960, Dallas, TX 75246 Ph: (214) 820-8030 | Mohammed Mogri, MD 3600 Gaston Avenue, Suite 960, Dallas, TX 75246 Ph: (214) 820-8030 |
News Archive
Researchers at the University of Toronto examined fungi in the mucus of patients with cystic fibrosis and discovered how one particularly cunning fungal species has evolved to defend itself against neighbouring bacteria.
A researcher from the University of Houston has created a form of recombinant insulin that could potentially address some of the biggest concerns about the lifesaving drug, including its price.
Researchers at the University of Cincinnati have received a $3.2 million grant from the National Institute of Neurological Diseases to study the use of neuroimaging to pinpoint the risk factors of stroke recurrence.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 5 days ago
Uma B.r.k Pakkivenkata, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |